Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRAVELLE vs ANDEMBRY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Ovulation induction in anovulatory women with polycystic ovary syndrome (PCOS),Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF)
Castration-resistant prostate cancer (chemotherapy-naïve or docetaxel-treated),Metastatic castration-resistant prostate cancer
For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
Terminal elimination half-life approximately 5-6 hours in healthy adults. Extended in renal impairment (up to 24 hours with Cr Cl <30 m L/min).
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
Primarily metabolized in the liver via renal excretion; metabolic pathways not fully characterized.
Hepatic via CYP3A4; active metabolites include abiraterone sulfate, abiraterone N-oxide, and abiraterone glucuronide.
Primarily renal: 95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal: 5% eliminated via feces.
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Approximately 10-20% bound to plasma proteins (albumin and α-1 acid glycoprotein).
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 0.3-0.5 L/kg. Distributing primarily in extracellular fluid; does not extensively penetrate tissues.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water and some tissue binding.
Subcutaneous: 90-95% bioavailable relative to intramuscular route. Oral: not clinically used due to enzymatic degradation.
Oral bioavailability is 85-90%; intravenous administration yields 100% bioavailability.
No specific guidelines exist for GFR-based dose modifications; use with caution in severe renal impairment (Cr Cl <30 m L/min) and monitor for adverse effects.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; avoid use.
No specific guidelines exist for Child-Pugh based modifications; use with caution in severe hepatic impairment and monitor for adverse effects.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate hepatic impairment (Child-Pugh B): reduce dose to 320 mg orally twice daily. Severe hepatic impairment (Child-Pugh C): not recommended.
Not indicated for use in pediatric patients; safety and efficacy not established.
Safety and efficacy not established in pediatric patients (<18 years); no recommended dose.
Not indicated for use in geriatric patients; safety and efficacy not established.
No specific dose adjustment required based on age. Monitor renal function and for increased risk of adverse events (e.g., diarrhea, hyperglycemia) in elderly patients.
Bravelle should only be used by physicians who are experienced in infertility treatment and can manage potential serious adverse events, including ovarian hyperstimulation syndrome (OHSS) and multiple gestations.
None.
Ovarian enlargement and ovarian hyperstimulation syndrome (OHSS) – can lead to serious complications; discontinue treatment if OHSS is suspected.,Multiple gestations – increased risk of multiple births.,Ovarian torsion – report sudden abdominal pain.,Pulmonary and vascular complications – thromboembolic events; discontinue if suspected.,Ectopic pregnancy and spontaneous abortion – higher rates in ART patients.,Neoplasms – risk of ovarian neoplasms with repeated use.
Hepatotoxicity, mineralocorticoid excess, cardiovascular events, adrenal insufficiency, and bone marrow suppression.
Hypersensitivity to urofollitropin or any component,High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Known or suspected pregnancy,Ovarian cyst or enlargement of undetermined origin,Abnormal uterine bleeding of undetermined origin,Sex hormone-dependent tumors (e.g., breast, uterus, ovary)
Hypersensitivity to abiraterone acetate or any component, severe hepatic impairment (Child-Pugh C), and women who are or may become pregnant.
No known food interactions. Maintain normal diet and hydration. Avoid alcohol as it may exacerbate side effects like nausea.
ANDEMBRY can be taken with or without food. However, grapefruit and grapefruit juice may increase trofinetide levels; avoid concurrent consumption. No other significant food interactions reported.
Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestations. Second and third trimesters: No direct fetal effects reported, but risks associated with multiple gestation (preterm birth, low birth weight). Maternal OHSS may lead to thromboembolism.
Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth restriction. Contraindicated in pregnancy.
Urofollitropin is not indicated for use during lactation. No data on excretion in human milk, M/P ratio not established. Use during breastfeeding is contraindicated due to potential for adverse effects on infant hormone levels.
Excreted in human milk; M/P ratio unknown. Potential for serious adverse effects in nursing infant. Contraindicated during breastfeeding.
No dose adjustment applicable as therapy is discontinued upon confirmed pregnancy. No pharmacokinetic data during pregnancy; drug is not used after conception due to contraindication.
Do not use in pregnancy. No dose recommendations available; contraindicated.
BRAVELLE (urofollitropin) is a purified FSH product used for controlled ovarian hyperstimulation. Administer subcutaneously; rotate injection sites. Monitor estradiol levels and follicle growth via ultrasound. Risk of ovarian hyperstimulation syndrome (OHSS); consider using Gn RH antagonist protocols to reduce risk. Do not administer if patient has high baseline FSH levels (>15 IU/L) indicating poor ovarian reserve.
ANDEMBRY (trofinetide) is indicated for the treatment of Rett syndrome. Administer orally twice daily with or without food. Monitor for diarrhea and vomiting, which are common adverse effects; consider dose reduction or temporary discontinuation if severe. Assess liver enzymes and bilirubin before and during treatment due to potential hepatotoxicity. Avoid use in patients with severe hepatic impairment. Do not crush or chew capsules; for patients unable to swallow, sprinkle contents onto soft food and administer immediately.
Teach proper injection technique and site rotation (abdomen, thigh).,Report immediately if severe pelvic pain, nausea, vomiting, or rapid weight gain occurs (OHSS signs).,Avoid intercourse until instructed to prevent multiple pregnancy.,Inform of multiple pregnancy risk (especially twins).,Store vials in refrigerator (2-8°C) and protect from light.
Take ANDEMBRY exactly as prescribed, twice daily with or without food.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.,Common side effects include diarrhea and vomiting; inform your doctor if these become severe or persistent.,Avoid alcohol while taking this medication as it may increase the risk of liver injury.,Report any signs of liver problems such as yellowing of skin or eyes, dark urine, or abdominal pain.,Do not crush or chew the capsules; if you have trouble swallowing, open the capsule and mix the contents with a small amount of soft food (e.g., applesauce) and take immediately.,Keep this medication out of reach of children and store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRAVELLE vs ANDEMBRY, answered by our medical review team.
BRAVELLE is a Gonadotropin that works by Bravelle (urofollitropin) is a purified preparation of follicle-stimulating hormone (FSH) that stimulates ovarian follicular growth and maturation by binding to FSH receptors on granulosa cells, increasing c AMP production and promoting follicular development.. ANDEMBRY is a Gonadotropin that works by Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRAVELLE and ANDEMBRY depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRAVELLE is: For ovulation induction: 150 IU subcutaneously or intramuscularly once daily for 5 days, starting on day 3 or 5 of menstrual cycle. For controlled ovarian hyperstimulation: 150-225 IU subcutaneously or intramuscularly once daily for 5-7 days, then adjust based on response.. The standard adult dose of ANDEMBRY is: ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRAVELLE and ANDEMBRY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRAVELLE is classified as Category C. Pregnancy Category X. Urofollitropin is contraindicated in pregnant women due to risk of fetal harm. First trimester: Ovarian hyperstimulation syndrome (OHSS) and multiple gestatio. ANDEMBRY is classified as Category C. Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth res. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.